Name: BIOGEN INC (BIIB) Stock
Brand: BIOGEN INC
Rating: 7 (3 reviews)

BIIB Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Chartmill - Mentions: APA ALB IBKR GILD ...

Explore the top gainers and losers within the S&P500 index in today's session.

a day ago - By: Biogen Inc. - Mentions: STOK

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

a day ago - By: Biogen Inc.

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

a day ago - By: Biogen Inc. - Mentions: IONS

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

a day ago - By: Biogen Inc.

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

4 days ago - By: Biogen Inc. - Mentions: IONS

Biogen Completes Acquisition of Alcyone Therapeutics

4 days ago - By: Biogen Inc.

Biogen Completes Acquisition of Alcyone Therapeutics

5 days ago - By: Biogen Inc.

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom

5 days ago - By: Zacks Investment Research - Mentions: JNJ LLY ABBV

Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month

11 days ago - By: Zacks Investment Research - Mentions: ALKS DNLI TAK

DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug

15 days ago - By: Biogen Inc.

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025

15 days ago - By: Biogen Inc.

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025

19 days ago - By: Zacks Investment Research - Mentions: AZN NVS IONS

Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook

19 days ago - By: Zacks Investment Research

Biogen (BIIB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

19 days ago - By: Investor's Business Daily

Biogen Sinks Back Into A Buy Zone After Cutting Its Profit Guide

19 days ago - By: Benzinga - Mentions: IR CDP ENTG BUD ...

Earnings Scheduled For October 30, 2025

19 days ago - By: Bloomberg

Biogen Cuts Profit Guidance After Deals to Bolster Pipeline

20 days ago - By: Benzinga

Examining the Future: Biogen's Earnings Outlook

23 days ago - By: Biogen Inc.

Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease

25 days ago - By: Stocktwits - Mentions: MODL XRMI

Biogen Licenses Vanqua Bio’s Immunology Drug In $1.06B Deal

25 days ago - By: Biogen Inc.

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

25 days ago - By: Biogen Inc.

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

a month ago - By: Zacks Investment Research

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

a month ago - By: Biogen Inc.

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

a month ago - By: Biogen Inc.

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

a month ago - By: The Motley Fool - Mentions: MSFT AAPL GS ETN

J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround

a month ago - By: Biogen Inc.

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

a month ago - By: Biogen Inc.

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

a month ago - By: Eisai Inc.

BIOGEN INC (BIIB) Stock News

BIIB Latest News, Press Relases and Analysis

Explore the top gainers and losers within the S&P500 index in today's session.

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy

Biogen Completes Acquisition of Alcyone Therapeutics

Biogen Completes Acquisition of Alcyone Therapeutics

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom

Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month

DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025

Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025

Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook

Biogen (BIIB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Biogen Sinks Back Into A Buy Zone After Cutting Its Profit Guide

Earnings Scheduled For October 30, 2025

Biogen Cuts Profit Guidance After Deals to Bolster Pipeline

Examining the Future: Biogen's Earnings Outlook

Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease

Biogen Licenses Vanqua Bio’s Immunology Drug In $1.06B Deal

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"